Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Nat Rev Drug Discov. 2017 Aug;16(8):531-543. doi: 10.1038/nrd.2017.111. Epub 2017 Jul 7.

Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Author information

1
Biochemical &Cellular Pharmacology, Genentech, South San Francisco, California 94080, USA.
2
Discovery Sciences, Primary Pharmacology Group, Pfizer, Groton, Connecticut 06340, USA.
3
Department of Quantitative Biology, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
4
Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
5
Phenotype and Target ID, Chemical Biology, pRED, Roche, 4070 Basel, Switzerland. Present address: Office of Innovation, Immunology, Infectious Diseases &Ophthalmology (I2O), Roche Late Stage Development, 124 Grenzacherstrasse, 4070 Basel, Switzerland.

Abstract

Phenotypic drug discovery (PDD) approaches do not rely on knowledge of the identity of a specific drug target or a hypothesis about its role in disease, in contrast to the target-based strategies that have been widely used in the pharmaceutical industry in the past three decades. However, in recent years, there has been a resurgence in interest in PDD approaches based on their potential to address the incompletely understood complexity of diseases and their promise of delivering first-in-class drugs, as well as major advances in the tools for cell-based phenotypic screening. Nevertheless, PDD approaches also have considerable challenges, such as hit validation and target deconvolution. This article focuses on the lessons learned by researchers engaged in PDD in the pharmaceutical industry and considers the impact of 'omics' knowledge in defining a cellular disease phenotype in the era of precision medicine, introducing the concept of a chain of translatability. We particularly aim to identify features and areas in which PDD can best deliver value to drug discovery portfolios and can contribute to the identification and the development of novel medicines, and to illustrate the challenges and uncertainties that are associated with PDD in order to help set realistic expectations with regard to its benefits and costs.

PMID:
28685762
DOI:
10.1038/nrd.2017.111
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center